1.Use of multiplex molecular respiratory panel in COVID-19 patients with suspected co-infections Insights and considerations in results interpretation
Nawi A.S. ; Engku Abd Rahman E.N.S. ; Nik Zuraina N.M.N. ; Musa N. ; Salleh M.Z. ; Samsudin M.N.F. ; Chua W.C. ; Muhd Besari A. ; Hassan R. ; Chan Y.Y.
Tropical Biomedicine 2025;42(No. 1):21-26
As critically ill COVID-19 patients are prone to infections by other respiratory pathogens, this study aimed
to investigate the detection of respiratory co-pathogens in such patients, by employing a multiplex
respiratory molecular panel. Conducted at Universiti Sains Malaysia Specialist Hospital (HPUSM) from
November 1, 2021, to November 1, 2022, this retrospective cross-sectional study analysed adults
admitted with confirmed COVID-19. Oropharyngeal/ nasopharyngeal swabs collected upon admission
were tested using the Fast Track Diagnostic (FTD®) Respiratory Pathogens 33 multiplex kit to detect
other respiratory pathogens. Within 48 hours of admission, the presence and type of organisms were
determined to assess community co-infections. Among 48 critically ill COVID-19 patients (26 male; mean
age, 62.2 years), clinically significant organisms were found in 32 patients (67%). Bacterial co-infections
or co-colonization were detected in 91% (29/32) of these patients, with Klebsiella pneumoniae (40%) and
Staphylococcus aureus (23%) were the most common, followed by Streptococcus pneumoniae (11%),
Moraxella catarrhalis (4%), and Haemophilus influenzae (2%). Fungal (6%) and viral (2%) co-infections
were less frequent. The use of syndromic respiratory panel in critically ill COVID-19 patients offers the
advantage of being highly sensitive, rapid, and able to detect multiple pathogens. However, detection of
multiple respiratory pathogens needs to be interpreted with caution, taking into consideration patient’s
clinical and radiological findings, as well as quantitative molecular data.
2.Prevalence of Epstein-Barr virus infection in individuals with nasopharyngeal carcinoma in Malaysia: The first systematic review and meta-analysis
Engku Abd Rahman, E.N.S. ; Irekeola, A.A. ; Shueb, R.H. ; Mohamud, R. ; Mat Lazim, N. ; Abdullah, B. ; Chan, Y.Y.
Tropical Biomedicine 2022;39(No.1):89-98
Epstein-Barr virus (EBV) was the first herpesvirus associated to human malignancies. Despite
the well-known association between EBV and malignancies, the prevalence of EBV infection
in Malaysians with malignancies is unknown. Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) was used to conduct a systematic review and metaanalysis of published data in this study. Studies reporting the occurrence of EBV infection in
Malaysian malignancy patients were searched in electronic databases like PubMed, Scopus,
ScienceDirect, and Google Scholar without year or language constraints. The study protocol
was filed in PROSPERO (CRD42021273769). A total of 21 studies were included, with 1,036 EBV
infection cases among 2,078 malignancy patients. The random-effects model was used to
produce summary estimates. The pooled prevalence of EBV infection in Malaysians with
malignancy was 36.3% (95% CI, 20.3 – 56.2). When the prevalence estimates were stratified by
malignancy type, nasopharyngeal carcinoma has the highest prevalence (90.5%), followed
by lymphoma (23.4%), and gastric carcinoma (10.0%). Male patients had a higher cases
prevalence and most patients were above the age of 40. In Malaysia, many malignancies are
increasingly linked to EBV infection. Screening for EBV infection in malignancy patients is
therefore important to determine disease recurrence and metastases.


Result Analysis
Print
Save
E-mail